BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease
Posted by amanda punzalan under Press (No Respond)
PALO ALTO and SOUTH SAN FRANCISCO, Dec. 7, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Maze Therapeutics today announced the establishment of a joint venture, Contour Therapeutics, focused on transforming and advancing breakthrough precision medicine approaches designed to treat…